Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Assets Average (2021 - 2025)

Historic Assets Average for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $1.0 billion.

  • Janux Therapeutics' Assets Average rose 4836.5% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 4836.5%. This contributed to the annual value of $721.0 million for FY2024, which is 9369.83% up from last year.
  • Per Janux Therapeutics' latest filing, its Assets Average stood at $1.0 billion for Q3 2025, which was up 4836.5% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Assets Average ranged from a high of $1.1 billion in Q1 2025 and a low of $347.2 million during Q2 2023
  • Moreover, its 5-year median value for Assets Average was $385.5 million (2021), whereas its average is $568.1 million.
  • As far as peak fluctuations go, Janux Therapeutics' Assets Average plummeted by 789.24% in 2023, and later surged by 12893.7% in 2024.
  • Janux Therapeutics' Assets Average (Quarter) stood at $385.5 million in 2021, then dropped by 4.04% to $369.9 million in 2022, then increased by 3.72% to $383.6 million in 2023, then skyrocketed by 128.94% to $878.3 million in 2024, then increased by 17.1% to $1.0 billion in 2025.
  • Its Assets Average stands at $1.0 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.1 billion for Q1 2025.